In the May edition of Clinical Imaging, Vincenzo and Concetto Giuliano of the Breast Cancer Research Institute in Florida published an article entitled “Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts.” While their purpose was quite straightforward — to justify the cost-benefit of the judicious application of ABUS in conjunction with digital mammography for women with dense breasts — the implications of their findings could have profound consequences.
Their experimental design included two study groups, the control and test groups, in successive years that were followed prospectively for one year. The control group consisted of 4,076 asymptomatic women, all of whom had breast density of 50% or greater as determined by the full-field digital mammography (FFDM) system manufactured by Hologic. The test group consisted of 3,418 asymptomatic women who also had dense breasts, where FFDM was followed by ABUS evaluation using the Somo-V device from U-Systems (now a subsidiary of GE Healthcare).
In the control group the sensitivity and specificity of stand-alone FFDM were 76.0% and 98.2% respectively, with a cancer detection rate of 4.6 per 1,000 patients. All cancers were biopsy proven invasive ductal carcinomas. In the test group, who had FFDM followed by ABUS, the sensitivity and specificity were 97.7% and 99.7% respectively, while the cancer detection rate was 12.3 per 1,000. The findings would appear to be clear-cut: far fewer cancers will be missed if ABUS is added to digital mammography when screening women with dense breast tissue.
There are still challenges that need to be addressed before FFDM plus ABUS becomes a widely adopted screening approach. Because ABUS generates 3D data there are many images for the radiologist to evaluate, researchers are developing computer-assisted detection algorithms to shorten the process, while at CapeRay we are building our Aceso model that combines the two imaging modalities in a single platform.